Shanghai Fosun Pharmaceutical's subsidiary Fosun Pharma Anticancer plans to increase capital and expand shares.

Shanghai Fosun Pharmaceutical (02196) announced that on June 15, 2026, its controlling subsidiary Fosun Anticorruption and 4 investors signed a "Subscription Agreement" and "Shareholders Agreement", under which Fosun Anticorruption plans to issue a total of 11.4954 million shares at a price of RMB 84.207235 per share to the investors (approximately 12.15% of the total number of shares of the target company after this capital increase), including: external investors plan to contribute a total of RMB 418 million to subscribe for a total of 4.9639 million shares, and the Company's controlling subsidiary, Shanghai Fosun Pharmaceutical Industry (i.e. the direct controlling shareholder of Fosun Anticorruption), plans to contribute RMB 550 million to subscribe for 6.5315 million shares. The proceeds from this capital increase will be used for the daily operations of Fosun Anticorruption and/or its controlling subsidiaries, including further expanding the innovative research and development pipeline, strengthening core technologies, simultaneously advancing production base construction to enhance industrial supply capabilities, and increasing market promotion and commercialization investment in products that are already listed. After completing the entire capital increase, it is expected that the Company will hold approximately 68.47% of the total shares of Fosun Anticorruption through Shanghai Fosun Pharmaceutical Industry (compared to approximately 70.08% before this capital increase), and Fosun Anticorruption will remain a subsidiary within the Group's consolidated financial statements.